Related Experiment Video
Updated: Jul 14, 2026
07:35
Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
Published on: June 1, 2022
Coenzyme Q10 supplementation and heart failure
Uma Singh1, Sridevi Devaraj, Ishwarlal Jialal
1Laboratory for Atherosclerosis and Metabolic Research, University of California-Davis Medical Center, Sacramento, California 95817, USA.
Nutrition Reviews
|July 4, 2007
Summary
Cardiovascular disease (CVD) is a major health concern. Coenzyme Q10 (CoQ10), a vital antioxidant, shows promise as a supportive therapy for congestive heart failure, though more research is needed.
Area of Science:
- Cardiology
- Biochemistry
- Gerontology
Background:
- Cardiovascular disease (CVD) is the primary cause of death globally.
- Oxidative stress is a key factor in the development of atherosclerosis.
- Coenzyme Q10 (CoQ10) is a crucial endogenous antioxidant whose production declines with age.
Purpose of the Study:
- To explore the role of Coenzyme Q10 (CoQ10) in cardiovascular health.
- To evaluate the potential therapeutic benefits of CoQ10 in managing congestive heart failure.
- To highlight the need for advanced research methods in assessing CoQ10's efficacy.
Main Methods:
- Literature review on oxidative stress and CoQ10.
- Analysis of existing studies on CoQ10 as an adjunct therapy for heart failure.
- Discussion of the necessity for advanced functional outcome assessment techniques.
Main Results:
- CoQ10, an essential antioxidant, plays a role in cellular health.
- Evidence suggests CoQ10 may benefit patients with congestive heart failure when used alongside standard treatments.
- Current research indicates a need for further investigation into CoQ10's therapeutic applications.
Conclusions:
- Coenzyme Q10 (CoQ10) is a significant antioxidant with potential therapeutic value in cardiovascular conditions.
- CoQ10 may serve as an effective adjunct therapy for congestive heart failure.
- Further research utilizing advanced methodologies is essential to fully understand CoQ10's impact on heart failure outcomes.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...